

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the “Issuer”)**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **24,712,424**

Date: **August 7, 2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.
- **The Corporation continues its business objectives as to its pre-clinical development plan and patent prosecution for its four families.**

On July 19, 2018 the Corporation announced that it has issued a total of 450,000 Class “A” shares (the “Shares”) pursuant to the second tranche (the “Second Tranche”) of it previously announced non-brokered private placement (“Private Placement”).

Pursuant to the Second Tranche, a total of 150,000 of the Shares were sold at a price per share of \$0.40 and Manitex Capital Inc. (“Manitex”), an insider of Ortho RTi, converted \$120,000 in principal balance owed to the Corporation into 300,000 Shares at a conversion price per share of \$0.40.

On July 31, 2018 the Corporation announced the extension of the expiry date of certain warrants which were issued in connection with private placements that closed prior to the listing of Ortho RTi’s shares on the CSE. The extended warrants, representing an aggregate of 2,107,500 warrants, originally expired in 2018 and 2019. Pursuant to the Warrant Term Extension, the expiry dates of the Warrants issued in conjunction with the Private Placements closed on August 3, 2016, March 31, 2017, April 27, 2017, June 28, 2017 and July 27, 2017 will be extended for one (1) year from their respective original maturity dates. All other terms of the Extended Warrants will remain unchanged.

2. Provide a general overview and discussion of the activities of management.

In the period, Management’s primary focus was to (i) continue to raise capital (ii) pursue the activities leading to our pre-clinical development path and manufacturing process (iii) maintain various discussions with well-known contract research organizations for our phase I/II humans’ trials.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Nothing applicable during the period.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Nothing applicable during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Nothing applicable during the period.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

The Corporation is indebted to Manitex Capital pursuant to a Note Payable dated July 28, 2017 for an amount of CDN\$249,711. On July 17, 2018, Manitex Capital agreed to accept, as partial settlement for an amount of \$120,000, by the issuance of 300,000 Class "A" Shares of the Corporation at a deemed price of \$0.40 per Share. Therefore, the remaining balance of the Note Payable is approximately \$129,711 and will continue to be owed pursuant to the terms and conditions of the Note Payable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Corporation made a deposit in the amount of \$ 54,321 to purchase an equipment to pursue its manufacturing process of its product to commence pivotal studies. The remaining amount to pay on delivery of the equipment is \$18,217.

8. Describe the acquisition of new customers or loss of customers.

Nothing applicable during the period.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Nothing applicable during the period.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Nothing applicable during the period.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Nothing applicable during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Nothing applicable during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Corporation has repaid in full its short-term debt in the amount of \$278,700 to a third-party lender. The debt bore interest at 1.5% per month and was secured by a first-rank moveable hypothec on its assets.

As mention in point 6, the Corporation settle the amount of \$120,000 on its note payable to Manitex by the issuance of shares. The remaining amount

as at July 31, 2018, is \$131,435. The Note payable is unsecured, bears interest at 12% per annum and is due on October 31, 2018.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common shares	150,000	At 0.40 per share	Clinical plan development and for working capital purposes
Common Shares	300,000	At 0.40 per shares	To settle a partial amount of \$120,000 from its Note Payable
Warrants	2,500	\$0.70 which expires in 18 months	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

No new loans with related parties in the current period

16. Provide details of any changes in directors, officers or committee members.

No change in the current period

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None in the current period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 7, 2018

Ortho Regenerative Technologies Inc.
/s/ Jo-Anne Mainguy-Piché
VP Finance & Chief Financial Officer
Official Capacity

<i>Issuer Details</i> Name of Issuer Ortho Regenerative Technologies Inc.	For Month End July 2018	Date of Report YY/MM/D 2018/08/07
Issuer Address 166667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.782.0951
Contact Name Jo-Anne M. Piché	Contact Position VP Finance & CFO	Contact Telephone No. 514.782.0951
Contact Email Address Piche@orthorti.com	Web Site Address www.orthorti.com	